Tamtam Try Tamtam free
IMCD Group logo

IMCD Group account plan

Chemical distribution and formulation

At a glance

IMCD distributes and formulates speciality chemicals and ingredients in over 60 countries, with FY2025 revenue of EUR 4,778.9 million.

IMCD N.V., founded in Rotterdam in 1995 and listed on Euronext Amsterdam since 2014, distributes and formulates speciality chemicals and ingredients for more than 71,000 active customers on behalf of over 3,000 suppliers. It runs an asset-light model: 123 offices and 86 laboratories and technical centres, with physical distribution outsourced to third-party logistics partners. In FY2025 it reported revenue of EUR 4,778.9 million (+1%), operating EBITA of EUR 497.8 million (-6%) and a net result of EUR 217.5 million, with 5,246 employees. The business is organised as a matrix of regional country P&Ls (EMEA, Americas, Asia-Pacific) and eight global Business Groups across Life Science and Industrial markets.

Business units

Strategic priorities

Return profit to historical levels
The CEO's stated ambition is to bring profit indicators back to historical levels after FY2025 operating EBITA fell 6% and the EBITA margin dropped to 10.4% from 11.2%.
Organic growth from supplier mandates
Management reaffirmed medium-term guidance of around 6%-7% organic gross profit growth and reports new supplier mandate wins as suppliers outsource more of their sales organisation.
Digital and AI-enabled selling
IMCD launched its SalesAssistant sales-enablement platform globally in 2025, runs the MyIMCD customer portal on a single ERP/CRM backbone, and is adding a fully automated pre-visit summary for salespeople.
Fix the Americas
Regional management has been strengthened and the US coast-to-coast supplier model is being expanded, after Americas organic EBITA fell 8% in the first nine months of 2026.
Selective acquisitions
IMCD completed seven acquisitions in 2025 adding EUR 319.5 million annualised revenue and three more in 2026, while stating it is not in a rush to close deals.
Emissions reduction
IMCD targets a 60% reduction in absolute Scope 1 and 2 emissions by 2034 from a 2024 baseline and is filing its SBTi near-term targets for validation.

Latest results

In the first nine months of 2026 revenue rose 8% to EUR 3,965 million (+10% at constant currency), operating EBITA rose 8% to EUR 425 million and the net result reached EUR 211 million. Momentum built through the year: organic gross profit growth went from -4% in Q1 to +7% in Q2 and +10% in Q3, and Q3 operating EBITA grew 18% with 14% organic growth across all segments. Free cash flow rose 12% to EUR 317 million and net debt fell to EUR 1,523.7 million, a leverage of 2.6x. EMEA and Asia-Pacific drove growth while the Americas still declined. IMCD gives no numeric outlook but expects organic operating EBITA growth in 2026.

Investments and deals

2025 acquisitions
Seven deals in 2025 (YCAM, Daoqin, Ferrer Alimentación, Trichem, TECOM, Apus Quimica, Tillmanns) added EUR 319.5 million annualised revenue; acquisition-related payments were EUR 437.2 million.
2026 acquisitions
Dong Yang FT (Korea, cosmetic ingredients) closed in January 2026, Willows Ingredients (Ireland/UK, food and nutrition) in March 2026, and Merit Solution (Thailand, plastics additives) on 25 August 2026.
Laboratories
Six new or upgraded laboratories opened in 2025, including a Life Science Laboratory hub in Shanghai and a Food & Nutrition lab in Jakarta.
Credit facility
The revolving credit facility was increased by EUR 100 million to EUR 700 million on 27 January 2026.
Restructuring
FY2025 one-off costs of EUR 25.1 million included EUR 14.8 million of restructuring and severance; holding costs were cut 15% to EUR 33.4 million and the back office rationalised for a net saving of about 200 employees.

Challenges and risks

Weak Americas
The CFO called the Americas outcome disappointing: nine-month 2026 EBITA fell 10% with a 9.5% margin, as North American coatings and construction demand stays weak.
Margin pressure from acquisitions
Gross margin was 24.9% in H1 2026 versus 25.6%, partly because recently acquired companies carry lower margins.
Unpredictable demand
IMCD states that macro-economic and political uncertainty make demand difficult to predict, and customers continue to order just-in-time.
Supplier dependency and currency
Top risks include supplier dependency, where losing a major supplier could be material, and currency volatility rated high likelihood; currency cost EUR 12 million of EBITA in H1 2026.
Chinese competition
Management says competition from China is present in the Americas, without significant change between Q2 and Q3 2026.

What leadership says

“It is clear that our partners need us now more than ever”

Marcus Jordan, Chief Executive Officer · First nine months 2026 results conference call, 5 November 2026

“The third quarter showed sustained business momentum, with healthy free cash flow and 14% organic EBITA growth, with contributions from all regions.”

Marcus Jordan, Chief Executive Officer · First nine months 2026 results release, 5 November 2026

“So far, we have a structure that can cope with more sales than what we have today, thanks to all the digital developments and thanks to the additional salespeople”

Hans Kooijmans, Chief Financial Officer · Half-year 2026 results conference call, 29 July 2026

Where a supplier can help

Sales-enablement and AI tooling
Tied to the digital and AI-enabled selling priority: SalesAssistant and automated pre-visit summaries show IMCD is investing in tools that make its frontline commercial teams more effective.
Commercial excellence in the Americas
Tied to the Americas challenge: management says the fix is strengthening commercial excellence rather than extra investment, an opening for sales-performance and market-coverage support.
Acquisition integration
Tied to the acquisition programme: ten deals across 2025 and 2026 need integrating onto IMCD's single ERP/CRM backbone, where integration services and data migration help.
Laboratory and formulation equipment
Tied to the laboratory investments: new and upgraded labs and rising formulation projects create demand for lab equipment and technical services.
Emissions reporting
Tied to the emissions-reduction priority: the SBTi filing and a 60% Scope 1 and 2 reduction target call for carbon accounting and energy-efficiency support across offices and labs.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like IMCD Group?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about IMCD Group

What does IMCD do?

IMCD distributes and formulates speciality chemicals and ingredients, connecting over 3,000 suppliers with more than 71,000 active customers. It provides technical advice and formulation support through 86 laboratories and technical centres while outsourcing physical logistics.

What is IMCD's revenue?

IMCD reported FY2025 revenue of EUR 4,778.9 million and operating EBITA of EUR 497.8 million. In the first nine months of 2026 revenue was EUR 3,965 million, up 8%.

How many employees does IMCD have?

IMCD had 5,246 employees at the end of 2025 and an FTE count of 5,264 at the end of September 2026.

Who leads IMCD?

Marcus Jordan has been CEO since April 2025. Hans Kooijmans, CFO since 1996, retires at the end of 2026 and is succeeded by Floris Lagerwerf.

What is IMCD's strategy?

IMCD aims to lead in every market its eight Business Groups serve, growing organically through supplier partnerships and technical solutions and through selective acquisitions, under six pillars: people, portfolio expansion, commercial, operational and digital excellence, and sustainability.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)